The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT)

Henrik Wiggers*, Lars Køber, Gunnar Gislason, Morten Schou, Mikael Kjær Poulsen, Søren Vraa, Olav Wendelbo Nielsen, Niels Eske Bruun, Helene Nørrelund, Malene Hollingdal, Anders Barasa, Morten Bøttcher, Karen Dodt, Vibeke Brogaard Hansen, Gitte Nielsen, Anne Sejr Knudsen, Jens Lomholdt, Kirsten Vilain Mikkelsen, Bartlomiej Jonczy, Jens Brønnum-SchouMonica Petronela Poenaru, Jawdat Abdulla, Ilan Raymond, Kiomars Mahboubi, Karen Sillesen, Kristine Serup-Hansen, Jette Sandberg Madsen, Søren Lund Kristensen, Anders Hostrup Larsen, Hans Erik Bøtker, Christian Torp-Petersen, Hans Eiskjær, Jacob Møller, Christian Hassager, Flemming Hald Steffensen, Bo Martin Bibby, Jens Refsgaard, Dan Eik Høfsten, Søren Mellemkjær, Finn Gustafsson*

*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

20 Citations (Scopus)

Fingerprint

Dive into the research topics of 'The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT)'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science